Protalix Biotherapeutics reported a 170% increase in Q1 product sales to $10 million, driven by higher sales to Pfizer and Brazil's Fiocruz, while narrowing its net loss to $3.6 million.
Protalix BioTherapeutics has completed a Phase I trial for PRX-115, demonstrating positive safety profile and prolonged urate-lowering effects in gout patients. The study results suggest potential advantages over current treatments, including reduced infusion frequency compared to existing therapies like Krystexxa.
Protalix BioTherapeutics announced the validation by the EMA of Chiesi's variation submission for pegunigalsidase alfa, aiming for less frequent dosing for Fabry disease.
Protalix BioTherapeutics' PRX-115, a PEGylated uricase, shows promising dose-dependent urate-lowering effects in a Phase 1 study for individuals with gout.